Androgen deprivation therapy (ADT) has long been the cornerstone of treatment for advanced prostate cancer. Since ...
Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered. Based on new findings in ...
A PHASE 1/2 clinical trial has reported encouraging early outcomes for single-fraction stereotactic body radiotherapy (SBRT) ...
Recent advancements in the management of biochemical recurrence (BCR) following local treatment for prostate cancer (PCa), including the use of androgen receptor signaling inhibitors (ARSIs), have ...
PLYMOUTH MEETING, PA [April 28, 2026] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers—has published a new book explaining the latest evidence and expert ...
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...
Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...
The National Comprehensive Cancer Network ® (NCCN ®)-an alliance of leading cancer centers-has published a new book explaining the latest evidence and expert recommendations around prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results